During this summit, the Corporation will present Thykamine's Phase 2 clinical trial results in Atopic dermatitis and other targeted skin inflammatory therapeutic applications.
Details of the Oral presentation are as follows
Title: Thykamine A New Botanical Drug: A Serious Candidate for the treatment of Atopic dermatitis & Beyond.
Session: Emerging Clinical Candidates & Therapeutic Options
Date/Time:
About Thykamine
Thykamine, the first pharmaceutical product issued from Devonian's SUPREX platform, is a highly innovative product for the prevention and treatment of health conditions related to inflammation and oxidative stress including ulcerative colitis, atopic dermatitis, psoriasis, rheumatoid arthritis, and other autoimmune disorders. The anti-inflammatory, anti-oxidative and immunomodulatory properties of Thykamine have been demonstrated by a considerable number of in vitro and in vivo studies as well as in a Phase IIa clinical study in patients with mild-to-moderate distal ulcerative colitis and in a phase II clinical study in patients with mild-to-moderate atopic dermatitis. Both Thykamine and SUPREX platform are protected by several patents in
About Devonian
Devonian's flagship product, Thykamine, the first pharmaceutical product issued from Devonian's SUPREX platform, is a highly innovative product for the prevention and treatment of health conditions related to inflammation and oxidative stress. The anti-inflammatory, anti-oxidative and immunomodulatory properties of Thykamine have been demonstrated by a considerable number of in vitro and in vivo studies as well as in a Phase IIa clinical study in patients with Mild-to-Moderate distal Ulcerative Colitis and in a large phase 2 clinical trial in adult patients with Mild-to-Moderate Atopic Dermatitis.
Devonian is also involved in the development of high-value cosmeceutical products leveraging the same proprietary approach employed with their pharmaceutical offerings.
Forward Looking Statements
This press release contains forward-looking statements about Devonian's objectives, strategies and businesses that involve risks and uncertainties. These statements are 'forward-looking' because they are based on our current expectations about the markets we operate in and on various estimates and assumptions. Actual events or results may differ materially from those anticipated in these forward-looking statements if known or unknown risks affect our business, or if our estimates or assumptions turn out to be inaccurate. Such risks and assumptions include, but are not limited to, the approval of the
Contact:
Dr.
Tel: (514) 248-7509
Email: apboulet@groupedevonian.com
(C) 2022 Electronic News Publishing, source